Rafferty Asset Management
MBX

Rafferty Asset Management’s MBX Biosciences MBX Stock Holding History

Rafferty Asset Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,113
Closed -$256K – 1153
2025
Q4 		$256K Buy
+8,113
New +$197K ﹤0.01% 1027

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Rafferty Asset Management's MBX Position: Q1 2026 in Review

Rafferty Asset Management sold out of MBX Biosciences (MBX) in Q1 2026, closing a stake of 8,113 shares — an estimated $256K sold.

Rafferty Asset Management first reported a position in MBX in Q4 2025 and held it in 1 quarter. The position peaked at $256K in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Rafferty Asset Management reported no remaining MBX Biosciences position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 8,113 MBX Biosciences shares in Q1 2026, an estimated $256K.
  • Rafferty Asset Management first reported a position in MBX Biosciences in Q4 2025 and held it in 1 quarter.
  • Rafferty Asset Management's MBX Biosciences position peaked at $256K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.